A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
A phase 1/2 trial of Ruxolitinib and Fedratinib in myeloproliferative neoplasms, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) is a phase 1/2 interventional study registered as NCT04817007 by Bristol-Myers Squibb, with 216 participants enrolled, started 2021-03-22 and due to reach its primary completion in 2028-08-31. Interventions recorded: BMS-986158, Ruxolitinib and Fedratinib.
Similar pages
not linked directly; found by shared links- TrialStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialKRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb and the tag pipeline.
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtended Access of Momelotinib in Adults With Myelofibrosis
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.